CD274 and non-small cell lung carcinoma: PD-1 and programmed death-ligand 1 (PD-L1) inhibitors are used in the second-line treatment of NSCLC, and studies have shown that these inhibitors can be used as second-line treatments for advanced NSCLC [19, 20].